Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Biological: ABT-874Biological: etanerceptDrug: placebo
- Registration Number
- NCT00691964
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Brief Summary
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 347
- Diagnosis of Psoriasis for 6 mo.
- BSA 10%, PASI 12 or above, PGA 3 or above
- Previous exposure to either etanercept or ABT-874
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A ABT-874 - B etanercept - C placebo -
- Primary Outcome Measures
Name Time Method Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12 12 Weeks Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12 12 Weeks
- Secondary Outcome Measures
Name Time Method Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12 12 Weeks
Trial Locations
- Locations (35)
Site Reference ID/Investigator# 8471
🇺🇸Philadelphia, Pennsylvania, United States
Site Reference ID/Investigator# 9641
🇺🇸Miami, Florida, United States
Site Reference ID/Investigator# 8464
🇺🇸Boston, Massachusetts, United States
Site Reference ID/Investigator# 8468
🇺🇸Cincinnati, Ohio, United States
Site Reference ID/Investigator# 8460
🇺🇸Cleveland, Ohio, United States
Site Reference ID/Investigator# 8479
🇺🇸Arlington Heights, Illinois, United States
Site Reference ID/Investigator# 8467
🇺🇸Indianapolis, Indiana, United States
Site Reference ID/Investigator# 8478
🇺🇸Tucson, Arizona, United States
Site Reference ID/Investigator# 8462
🇺🇸Fresno, California, United States
Site Reference ID/Investigator# 8447
🇺🇸Albuquerque, New Mexico, United States
Site Reference ID/Investigator# 9762
🇺🇸Oklahoma City, Oklahoma, United States
Site Reference ID/Investigator# 8469
🇺🇸Portland, Oregon, United States
Site Reference ID/Investigator# 8454
🇺🇸Los Angeles, California, United States
Site Reference ID/Investigator# 8459
🇺🇸St. Louis, Missouri, United States
Site Reference ID/Investigator# 9001
🇺🇸Skokie, Illinois, United States
Site Reference ID/Investigator# 8473
🇺🇸East Windsor, New Jersey, United States
Site Reference ID/Investigator# 8457
🇺🇸New Brunswick, New Jersey, United States
Site Reference ID/Investigator# 8475
🇺🇸New York, New York, United States
Site Reference ID/Investigator# 8456
🇺🇸Greer, South Carolina, United States
Site Reference ID/Investigator# 8458
🇺🇸Goodlettsville, Tennessee, United States
Site Reference ID/Investigator# 8461
🇺🇸Austin, Texas, United States
Site Reference ID/Investigator# 10542
🇺🇸Dallas, Texas, United States
Site Reference ID/Investigator# 8452
🇺🇸Houston, Texas, United States
Site Reference ID/Investigator# 8474
🇺🇸San Antonio, Texas, United States
Site Reference ID/Investigator# 9566
🇺🇸Portland, Oregon, United States
Site Reference ID/Investigator# 8449
🇺🇸Johnston, Rhode Island, United States
Site Reference ID/Investigator# 8448
🇺🇸Providence, Rhode Island, United States
Site Reference ID/Investigator# 8463
🇺🇸Alpharetta, Georgia, United States
Site Reference ID/Investigator# 8527
🇺🇸Schaumburg, Illinois, United States
Site Reference ID/Investigator# 8466
🇺🇸West Dundee, Illinois, United States
Site Reference ID/Investigator# 8476
🇺🇸Denver, Colorado, United States
Site Reference ID/Investigator# 8480
🇺🇸Lake Oswego, Oregon, United States
Site Reference ID/Investigator# 8482
🇺🇸Tyler, Texas, United States
Site Reference ID/Investigator# 9761
🇺🇸Hershey, Pennsylvania, United States
Site Reference ID/Investigator# 8472
🇺🇸Norfolk, Virginia, United States